Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Curve vs REMEVi

Curve
Graded #289

Lower grade

vs+8.700000000000003
REMEVi
Graded #105

Higher grade

The verdict

REMEVi takes it — 70.4/100 to 61.7/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCurve +3
57
54
Dose & formulationEven
64
64
Clinical oversightREMEVi +18
68
86
Labs & monitoringREMEVi +13
52
65
FulfillmentEven
97
97
Contract termsREMEVi +49
20
69
Curve · left barREMEVi · right bar

The numbers

MetricCurveREMEVi
WeighScore61.7/10070.4/100
GradeCC
Scorecard rank#289#105
Semaglutide$175/mo (compounded)$199/mo (starting dose, compounded)
Tirzepatide$225/mo (compounded)$269/mo (starting dose, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Curve

Graded #289 · C

Strengths

  • Offers both compounded semaglutide and tirzepatide, with every dose priced the same so cost does not rise as you titrate up.
  • LegitScript-certified (seal #51079066) and names both its 503A compounding pharmacy, VialsRx, and its provider network, Beluga Health.
  • Transparent tiered pricing with a real month-to-month option; consultation, medication, and free expedited shipping included, no membership.
  • Available in all 50 states with same-day provider review; no insurance needed and HSA/FSA accepted.

Where it loses points

  • Very new (2026 launch) with a thin track record; the site still shows a Webflow template credit and a leftover Cora reference in its Terms.
  • The cheapest headline rates ($99 semaglutide / $135 tirzepatide) require a 12-month prepay; true month-to-month is $175 and $225.
  • Both product pages currently display an out-of-stock status, so availability may be inconsistent.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
REMEVi

Graded #105 · C

Strengths

  • The first bilingual GLP-1 clinic — care delivered in English and Spanish by clinicians trained in both, not auto-translated
  • Compounded semaglutide from $199/mo and tirzepatide from $269/mo on the 52-week plan, with the same price every month (no titration price hikes)
  • LegitScript-certified and licensed in all 50 states + DC, with an NPI-verified pharmacy and overnight shipping
  • Transparent all-inclusive pricing with no hidden fees and cancel anytime; full legal suite (Privacy, Terms, HIPAA, Refund)

Where it loses points

  • Lowest pricing requires a 52-week commitment — month-to-month is higher ($279 semaglutide / $339 tirzepatide)
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy or Zepbound
  • The specific compounding pharmacy is not named (described as 'NPI-verified')
  • A newer, patient-founded clinic; press mentions (Fortune, AP, Reuters) are syndicated PR, not editorial endorsements

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard